Encouraging results derived from preclinical studies on the antagonism of TLR4, but, in a trial on patients with biopsy-proven NASH, grade 1-3 fibrosis, and hypertransaminasemia JKB-121 did not reach the endpoint of reducing the liver fat content by MRI-PDFF and/or serum ALT after 24 weeks (264). Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.